AGOURA HILLS

Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023

Retrieved on: 
Friday, August 25, 2023
OTCQB, Translational medicine, Therapy, Patient, Center of excellence, Immunotherapy, Pharmaceutical industry, Nursing

AGOURA HILLS, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today it was featured in Life Sciences Review, Cancer Immunology Edition and has been awarded a Top Cancer Immunotherapy Solutions Provider 2023 with other aluminous organizations.

Key Points: 
  • AGOURA HILLS, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today it was featured in Life Sciences Review, Cancer Immunology Edition and has been awarded a Top Cancer Immunotherapy Solutions Provider 2023 with other aluminous organizations.
  • This edition features the Company’s science and planned clinical trials across multiple oncology indications and promising therapeutics.
  • This has given me the opportunity to focus on the treatment of patients, which is my passion.
  • I am honored for the recognition for both Oncotelic and me personally,” said Dr. Anthony Maida, Chief Clinical Officer - Translational Medicine.

Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer

Retrieved on: 
Wednesday, August 23, 2023
Biotechnology, TGF, FACP, Clinical trial, Cancer, Oligonucleotide, OTCQB, Woman, Medicine, FOLFIRINOX, MD, Physician, Randomness, Mortality, Therapy, Pharmaceutical industry, Fine chemical, EU, Pancreatic cancer, Cromos, Patient

The rates of pancreatic cancer are rising—and are rising faster among younger women, particularly Black women, than among men of the same age.

Key Points: 
  • The rates of pancreatic cancer are rising—and are rising faster among younger women, particularly Black women, than among men of the same age.
  • Addressing this urgent medical need, Oncotelic, through Sapu, is launching a registrational Phase 2b/Phase 3 trial with their TGF-β2 targeting therapy, OT-101 in combination with Standard of Care- (FOLFIRINOX) against pancreatic cancer.
  • Sapu has engaged Cromos Pharma, an international midsized CRO, to assist in the conduct of the trial.
  • Spearheaded by our discovery that suppression of TGFβ2 could more than double survival in pancreatic cancer, we have engineered the trial to deliver a decisive win against pancreatic cancer.

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 14, 2023
IPO, Axial spondyloarthritis, IV, Spermatogenesis, Nektar Therapeutics, Doctor of Philosophy, Pain, Graves' ophthalmopathy, Psoriatic arthritis, Dermatology, Teprotumumab, MD, Patient, Randomized controlled trial, Prurigo nodularis, DMC, Disease, Tissue, SLRN, Disability, Human, IL-17A, Data, Hearing, Uveitis, Rheumatology, Growth, FDA, Safety, D, Secukinumab, Neutropenia, Exercise, POC, Eosinophilic esophagitis, Allergy, B cell, AAD, Webcast, CFO, Enthesitis, LOS, Research, Hives, Therapy, Inflammation, Huber loss, CU, Data monitoring committee, TED, Pharmaceutical industry, Vaccine, Management, Rare-earth element, HS, Part, Hidradenitis suppurativa

LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.   

Key Points: 
  • LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.
  • Enrollment of the double-blind, placebo-controlled Part B of the Phase 2b/3 trial evaluating izokibep in HS completed ahead of schedule, accelerating anticipated top-line results into the third quarter 2023.
  • Net Loss: Net loss totaled $26.0 million for the second quarter of 2023, compared to $14.5 million for the second quarter of 2022.
  • ET to review its second quarter 2023 financial results.

ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023

Retrieved on: 
Monday, August 7, 2023
Webcast, SLRN, Pharmaceutical industry, Broadcasting, Video game

LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, August 14, 2023 at 4:30 p.m.

Key Points: 
  • LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, August 14, 2023 at 4:30 p.m.
  • ET to discuss its second quarter 2023 financial results and provide a corporate update.
  • A live webcast of the conference call will be available on the Company’s website under “Events” or at https://www.acelyrin.com/events .
  • A replay of the webcast will be available on the Company’s website for 90 days.

Bliss Car Wash CEO Vahid David Delrahim Details The Importance of Giving Back and the Festival Napa Valley

Retrieved on: 
Tuesday, July 25, 2023
Education, Face, Culture, Lead, Hope, Festival Napa Valley, Creativity, Makan Delrahim, Corporation, Growth, Empathy, Gala, Environment, Empowerment, Creative industries

One shining example of this commitment to making a positive impact is the Festival Napa Valley’s Arts for All Gala .

Key Points: 
  • One shining example of this commitment to making a positive impact is the Festival Napa Valley’s Arts for All Gala .
  • The Festival Napa Valley’s commitment to supporting arts education ensures that future generations can explore and cultivate their artistic talents.
  • The Festival Napa Valley’s Arts for All Gala exemplifies the spirit of giving back by establishing a sustainable future for the arts.
  • “As CEO of BLISS Car Wash , I am proud to support the Arts for All Gala and give back to the community.

ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer 

Retrieved on: 
Tuesday, July 18, 2023
Gilead Sciences, SLRN, University, Marketing, Dermatology, MBA, Rheumatology, Psoriasis, Patient, LOS, Cornell University, Autoimmunity, Inflammation, Pharmaceutical industry, MD, Pfizer

LOS ANGELES, July 18, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Ken Lock as Chief Commercial Officer, effectively immediately. Mr. Lock will report to Founder and Chief Executive Officer Shao-Lee Lin, MD, PhD and will serve on the Company’s Senior Leadership Team.

Key Points: 
  • ACEYLRIN currently has a robust portfolio including late-stage clinical trials underway supporting multiple potential commercial launches in coming years.
  • LOS ANGELES, July 18, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Ken Lock as Chief Commercial Officer, effectively immediately.
  • Lock will report to Founder and Chief Executive Officer Shao-Lee Lin, MD, PhD and will serve on the Company’s Senior Leadership Team.
  • Lock brings to ACELYRIN leading experience in the Dermatology and Rheumatology therapeutic areas, having most recently served as Chief Commercial Officer at Arcutis Biotherapeutics.

ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Thursday, June 15, 2023
Acceleration, Exercise, TED, SLRN, IPO, POC, IPR, D, Abscess, Enthesitis, Public, Quality of life, American Academy, Research, Doctor of Philosophy, Connective tissue, Graves' ophthalmopathy, Hidradenitis suppurativa, Psoriatic arthritis, Acquisition, MD, AAD, Patient, American Academy of Dermatology, LOS, Data monitoring committee, Hives, Neuro-ophthalmology, III, DMC, Disease, Autoimmunity, Inflammation, Life insurance, Pharmaceutical industry, HS

With the proceeds of our recent initial public offering, we will continue to drive towards key value-driving milestones to deliver efficiently on our development plans.

Key Points: 
  • With the proceeds of our recent initial public offering, we will continue to drive towards key value-driving milestones to deliver efficiently on our development plans.
  • Part B of the Phase 2b/3 trial completed enrollment early and top-line results are now anticipated in Q3 2023.
  • Net Loss: Net loss totaled $176.5 million for the first quarter of 2023, compared to $16.1 million for the first quarter of 2022.
  • This includes the one-time $123.1 million IPR&D charge and $10.0 million license payment, both related to the acquisition of ValenzaBio.

Oncotelic Launches PR Chatbot

Retrieved on: 
Monday, June 12, 2023
AI, OTCQB, Therapy, CBO, PR, Feedback, Customer service

AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), annouces the beta unveiling of a pioneering press releases (“PR”) chatbot.

Key Points: 
  • AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), annouces the beta unveiling of a pioneering press releases (“PR”) chatbot.
  • Our PR chatbot is open to all users, with no restriction on token holder status, thus inviting everyone to experience the seamless comparison of our PR chatbot with traditional ChatGPT.
  • As we refine and perfect our beta version of our PR chatbot, your insights and feedback are invaluable.
  • Saran Saund, CBO of Oncotelic, shared his perspective, " Launching this chatbot marks another milestone in our ongoing commitment to harness the power of AI technologies.

Ash Delrahim Explains How BLISS Car Wash is Embracing Environmental Stewardship

Retrieved on: 
Monday, May 22, 2023
Operation, Building material, Water quality, BLISS, Carbon, Climate change, World Water Day, Fresh water, Water, Transport, Health, Environment, Water resources, Fertilizer, Heating, ventilation, and air conditioning, Recycling

LOS ANGELES, May 22, 2023 (GLOBE NEWSWIRE) -- BLISS Car Wash recognizes the importance of environmental sustainability and water conservation in California.

Key Points: 
  • LOS ANGELES, May 22, 2023 (GLOBE NEWSWIRE) -- BLISS Car Wash recognizes the importance of environmental sustainability and water conservation in California.
  • As Ash Delrahim, Vice President of Operations at BLISS Car Wash , expressed in a recent panel discussion about sustainability and the industry’s future at The Car Wash Show in Las Vegas, the industry must recognize the significance of being environmentally focused while implementing water conservation in operations.
  • “BLISS takes a unique approach to reduce our environmental footprint by challenging the industry norm of building large 150-foot plus express wash tunnels.
  • Ash Delrahim explains four significant ways BLISS has changed the standard for sustainable car wash practices to help preserve the environment.

Oncotelic Participating at 2023 BIO International Convention

Retrieved on: 
Tuesday, May 16, 2023
IPO, Drug development, Therapy, TGF, Disease, Survival, Pancreatic cancer, Cancer, Parkinson's disease, Pharmaceutical industry

AGOURA HILLS, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a pioneering developer of therapeutic interventions for rare and orphan diseases such as Parkinson's Disease and various forms of cancer, is thrilled to announce their participation in the BIO International Convention.

Key Points: 
  • AGOURA HILLS, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a pioneering developer of therapeutic interventions for rare and orphan diseases such as Parkinson's Disease and various forms of cancer, is thrilled to announce their participation in the BIO International Convention.
  • The ongoing advancement of clinical trials for OT-101 in conjunction with P201 in Pancreatic Cancer, set to commence in the second half of 2023.
  • Additional combination trials with various checkpoint inhibitors involving multiple cancer types are also slated to begin within the same timeframe.
  • This platform is anticipated to revolutionize the drug development initiatives within both Oncotelic and the joint venture.